Jeil, started commercialization of JLP-1401

Combination of Telmisartan 80mg/Amlodipine 5mg/Rosuvastatin 5mg

Recently approved for phase I clinical trial to secure equivalence, product competitiveness and production expansion

Telmiduo Plus by Jeil

Jeil has begun commercializing a high blood pressure-hyperlipidemia three-drug, credit-quantity formulation.

 

It is a formulation that combines Telmisartan-Amlodipine-Rosuvastatin, and is known as a new product of Telmiduo Plus, which Jeil is already launching.

 

The MFDS approved the phase I clinical trial protocol of JLP-1401 submitted by Jeil on the 10th.

 

In this clinical trial, the pharmacokinetic properties and safety of Telmisartan/Amlodipine and Rosuvastatin and JLP-1401 administration will be compared and evaluated in healthy adult volunteers.

 

JLP-1401 is also the name of Telmiduo Plus, which was approved by Jeil in May 2018.

 

Telmiduo Plus has three doses with Telmisartan-Amlodipine-Rosuvastatin dosages of '40/5/10mg', '80/10/20mg' and '80/5/10mg' respectively.

 

Jeil directly develops and supplies contract production to Samjin, Unimed, Hana, and Myungmoon.

 

However, Rosuvastatin 5mg is missing, which has been evaluated as being inferior in market competitiveness.

 

Both Yuhan and Ildong, which produce the same generics, are releasing products containing Rosuvastatin 5mg.

 

In addition, Rosuvastatin 5mg was analyzed that the rate of reaching the target LDL-C control treatment target was high at 83.3% for males and 92.9% for females, even in a study of 1,851 Korean patients.

 

Accordingly, it seems that Jeil is developing an additional combination drug containing Rosuvastatin 5mg.

 

This is because Twynsta 80.5mg, a combination of Telmisartan-Amlodipine, and Crestor 5mg, containing Rosuvastatin are used as reference drugs for this clinical trial.

 

When new products are completed, it is expected that market competitiveness will improve and production will increase.

 

A total of 40 products of Telmisartan-Amlodipine-Rosuvastatin were approved.

 

According to UVIST, in the first half of this year, Ildong's Telostop Plus recorded about ₩1.6 billion, Yuhan's Duowell A about ₩900 million, and Jeil's Telmiduo Plus about ₩800 million.